AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
55 hedge funds and large institutions have $21.4M invested in AVEO Pharmaceuticals, Inc. in 2014 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 13 closing their positions.
10% less funds holding
Funds holding: 61 → 55 (-6)
28% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 18
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
49% less capital invested
Capital invested by funds: $42.3M → $21.4M (-$20.9M)
97% less call options, than puts
Call options by funds: $4K | Put options by funds: $124K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Gruss Capital Management
New York
|
+$1.05M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$274K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$216K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$191K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$190K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.25M |
| 2 |
FRM
Fore Research & Management
New York
|
-$1.23M |
| 3 |
Renaissance Technologies
New York
|
-$956K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$531K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$409K |
AVEO Hedge Fund Activity: Q3 2014 in Review
55 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q3 2014, worth a combined $21.4M — down 49% from $42.3M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of AVEO and 7 opened new positions — a net loss of 6 holders — while 18 trimmed existing stakes and 13 added.
The largest buyer was Gruss Capital Management, adding an estimated $1.05M. The largest seller was Great Point Partners, exiting entirely with an estimated $4.25M sold.
- 55 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q3 2014, down from 61 in Q2 2014.
- Funds reported $21.4M of AVEO Pharmaceuticals, Inc. stock for Q3 2014, down 49% quarter-over-quarter.
- 7 funds opened new AVEO Pharmaceuticals, Inc. positions in Q3 2014 and 13 closed out, a net change of -6 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q3 2014 was Gruss Capital Management, an estimated $1.05M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q3 2014 was Great Point Partners, an estimated $4.25M sold.
Based on aggregated 13F filings for Q3 2014.